Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Zhu, Jun" or (type any "bookEditor issueEditor" and editor="Zhu, Jun")

Add to list
Co-limitation towards lower latitudes shapes global forest diversity gradients

Jingjing Liang, Javier G. P. Gamarra, Nicolas Picard, Mo Zhou, Bryan Pijanowski, Douglass F. Jacobs, Peter B. Reich, Thomas W. Crowther, Gert-Jan Nabuurs, Sergio de-Miguel, et al.

(2022) NATURE ECOLOGY & EVOLUTION. 6(10). p.1423-1437
Add to list
Quality of primary health care in China : challenges and recommendations

Xi Li, Harlan M. Krumholz, Winnie Yip, Kar Keung Cheng, Jan De Maeseneer (UGent) , Qingyue Meng, Elias Mossialos, Chuang Li, Jiapeng Lu, Meng Su, et al.

(2020) LANCET. 395(10239). p.1802-1812
Add to list
- Journal Article
- A1
- open access
AUGMENT : a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma

John P Leonard, Marek Trneny, Koji Izutsu, Nathan H Fowler, Xiaonan Hong, Jun Zhu, Huilai Zhang, Fritz Offner (UGent) , Adriana Scheliga, Grzegorz S Nowakowski, et al.

(2019) JOURNAL OF CLINICAL ONCOLOGY. 37(14). p.1188-1199
Add to list
Oxidative stress-triggered interactions between the succinyl- and acetyl-proteomes of rice leaves

Heng Zhou, Iris Finkemeier, Wenxue Guan, Maria-Armineh Tossounian, Bo Wei, David Young, Jingjing Huang (UGent) , Joris Messens, Xibin Yang, Jun Zhu, et al.

(2018) PLANT CELL AND ENVIRONMENT. 41(5). p.1139-1153
Add to list
- Conference Paper
- C3
AUGMENT : a phase III randomized study of lenalidomide plus rituximab (R-2) vs rituximab/placebo in patients with relapsed/refractory indolent non-Hodgkin lymphoma

John P Leonard, Marek Trneny, Koji Izutsu, Nathan H Fowler, Xiaonan Hong, Jun Zhu, Huilai Zhang, Fritz Offner (UGent) , Adriana Scheliga, Grzegorz S Nowakowski, et al.

(2018) BLOOD. 132(suppl. 1).
Add to list
- Journal Article
- A1
- open access
Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories : a systematic analysis for the Global Burden of Disease Study 2017

Rafael Lozano, Nancy Fullman, Degu Abate, Solomon M Abay, Cristiana Abbafati, Nooshin Abbasi, Hedayat Abbastabar, Foad Abd-Allah, Jemal Abdela, Ahmed Abdelalim, et al.

(2018) LANCET. 392(10159). p.2091-2138
Add to list
- Conference Paper
- C3
A phase III study of enzastaurin in patients with high-risk diffuse large B cell lymphoma following response to primary treatment: the prelude trial

Michael Crump, Sirpa Leppa, Luis E Fayad, Je-Jung Lee, Alice Di Rocco, Michinori Ogura, Hans Hagberg, Frederick Schnell, Robert M Rifkin, Andreas Mackensen, et al.

(2013) BLOOD. 122(21).

Academic Bibliography

Co-limitation towards lower latitudes shapes global forest diversity gradients

Quality of primary health care in China : challenges and recommendations

AUGMENT : a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma

Oxidative stress-triggered interactions between the succinyl- and acetyl-proteomes of rice leaves

AUGMENT : a phase III randomized study of lenalidomide plus rituximab (R-2) vs rituximab/placebo in patients with relapsed/refractory indolent non-Hodgkin lymphoma

Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories : a systematic analysis for the Global Burden of Disease Study 2017

A phase III study of enzastaurin in patients with high-risk diffuse large B cell lymphoma following response to primary treatment: the prelude trial

Contents

Support

Contact